IcICLLe: Assessment of the Mechanism of Action of Ibrutinib (PCI-32765) in B-cell Receptor Pathway Inhibition in CLL.

Trial Profile

IcICLLe: Assessment of the Mechanism of Action of Ibrutinib (PCI-32765) in B-cell Receptor Pathway Inhibition in CLL.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms IciCLLe
  • Most Recent Events

    • 25 Jun 2017 Initial results (n=31) from extension study presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Results of exploratory end points presented at the 22nd Congress of the European Haematology Association.
    • 06 Dec 2016 Results from the extension study (n=17) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top